Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
Published
Journal Article (Review)
The burden that Parkinson's disease (PD) exacts on the population continues to increase year after year. Though refinement of symptomatic treatments continues at a reasonable pace, no accepted therapies are available to slow or prevent disease progression. The leucine-rich repeat kinase 2 (LRRK2) gene was identified in PD genetic studies and offers new hope for novel therapeutic approaches. The evidence linking LRRK2 kinase activity to PD susceptibility is presented, as well as seminal discoveries relevant to the prosecution of LRRK2 kinase inhibition. Finally, suggestions are made for predictive preclinical modeling and successful first-in-human trials.
Full Text
Duke Authors
Cited Authors
- West, AB
Published Date
- February 2015
Published In
Volume / Issue
- 30 / 2
Start / End Page
- 180 - 189
PubMed ID
- 25448543
Pubmed Central ID
- 25448543
Electronic International Standard Serial Number (EISSN)
- 1531-8257
Digital Object Identifier (DOI)
- 10.1002/mds.26075
Language
- eng
Conference Location
- United States